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The matricellular proteins, secreted protein acidic and rich in cysteine (SPARC)
and SPARC-like 1 (SPARCL1), are produced by astrocytes and control excitatory
synaptogenesis in the central nervous system. While SPARCL1 directly promotes
excitatory synapse formation in vitro and in the developing nervous system in vivo,
SPARC specifically antagonizes the synaptogenic actions of SPARCL1. We hypothesized
these proteins also help maintain existing excitatory synapses in adult hosts, and that
local inflammation in the spinal cord alters their production in a way that dynamically
modulates motor synapses and impacts the severity of paralysis during experimental
autoimmune encephalomyelitis (EAE) in mice. Using a spontaneously remitting EAE
model, paralysis severity correlated inversely with both expression of synaptic proteins
and the number of synapses in direct contact with the perikarya of motor neurons in
spinal gray matter. In both remitting and non-remitting EAEmodels, paralysis severity also
correlated inversely with sparcl1:sparc transcript and SPARCL1:SPARC protein ratios
directly in lumbar spinal cord tissue. In vitro, astrocyte production of both SPARCL1 and
SPARC was regulated by T cell-derived cytokines, causing dynamic modulation of the
SPARCL1:SPARC expression ratio. Taken together, these data support a model whereby
proinflammatory cytokines inhibit SPARCL1 and/or augment SPARC expression by
astrocytes in spinal gray matter that, in turn, cause either transient or sustained synaptic
retraction from lumbar spinal motor neurons thereby regulating hind limb paralysis during
EAE. Ongoing studies seek ways to alter this SPARCL1:SPARC expression ratio in favor
of synapse reformation/maintenance and thus help tomodulate neurologic deficits during
times of inflammation. This could identify new astrocyte-targeted therapies for diseases
such as multiple sclerosis.
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Introduction
Multiple sclerosis (MS) is a common autoimmune disorder of
the central nervous system (CNS), and most patients come to
medical attention with a relapsing-remitting form of disease
(RRMS). Pathological examination of affected CNS tissue shows
focal areas of demyelination, often associated with underlying
axonal damage, accompanied by varying amounts of immune
cell infiltration. The formation of new demyelinating lesions
is widely presumed to be the main tissue substrate of clinical
relapses, and magnetic resonance imaging (MRI) scans of the
brain and spinal cord can detect even small demyelinating
lesions in RRMS patients in real time. MRI scans obtained
following the intravenous infusion of a paramagnetic contrast
material also reveal active blood-brain barrier (BBB) breakdown
in white matter plaques, and clinical-radiological-pathological
correlations show that these contrast-enhancing lesions represent
new areas of active immune-mediated demyelination (Li et al.,
2006; Filippi et al., 2012; Sormani and Bruzzi, 2013; Simon,
2014). Clinical remission is associated with a resolution of BBB
breakdown on MRI scans (Li et al., 2006; Filippi et al., 2012;
Sormani and Bruzzi, 2013; Simon, 2014), but the cellular and
molecular substrates of recovery following an MS exacerbation
still remain poorly understood. In the experimental autoimmune
encephalomyelitis (EAE) model of MS, a relapsing-remitting
disease can be provoked in SJL mice following immunization
with a peptide of proteolipid protein (PLP) or via the adoptive
transfer of polarized CD4+ T cells derived from PLP-immunized
mice. This experimental system has been extensively studied to
gain mechanistic insight into MS relapses and remissions.
Based on growing evidence of gray matter pathology in MS
(Vercellino, 2005; Stadelmann et al., 2008; Geurts et al., 2012;
Calabrese et al., 2015), the occurrence and persistence of synaptic
abnormalities has become an emerging area of investigation
in both MS and EAE. Numerous studies now show direct
tissue evidence of reduced synapse density (Vercellino, 2005;
Stadelmann et al., 2008; Michailidou et al., 2015), or reduced
expression of pre- and post-synaptic proteins (Vercellino, 2005),
in gray matter lesions from MS autopsy specimens. Such
investigations are, however, focused on more advanced stages
of disease and by definition cannot assess synaptic function or
identify synaptic plasticity over time. In both rat and mouse
EAE models, synaptic abnormalities have been described in the
cortex, hippocampus and lumbar spinal cord immediately prior
to or just at the time clinical symptoms emerge (Zhu et al.,
2003; Marques et al., 2006; Centonze et al., 2009; Freria et al.,
2010; Ziehn et al., 2010; Yang et al., 2013; Di Filippo et al., 2015;
Mandolesi et al., 2015), and data suggest these synaptic changes
can reverse themselves in animals that undergo clinical recovery
(Zhu et al., 2003; Marques et al., 2006; Centonze et al., 2009;
Freria et al., 2010; Yang et al., 2013;Mandolesi et al., 2015). In vivo
two-photon microscopy has been used to image axonal boutons
and dendritic spines in the cortices of mice with EAE in real time
and shows notable synaptic instability driven by the release of
soluble inflammatory mediators (Yang et al., 2013). If synaptic
and/or dendritic changes are important contributors to the
neurological deficits that occur in EAE andMS, then an improved
understanding of the molecular mechanisms controlling these
events could have therapeutic relevance.
Astrocytes are now recognized to play important roles in
synaptic development and plasticity (Clarke and Barres, 2013;
Haydon and Nedergaard, 2014; De Pittà et al., 2015). Not
only do these cells release transmitters that modulate synaptic
activity (Allen and Barres, 2005), but they also control the actual
formation, maturation, and elimination of synapses through both
secreted and cell contact-dependent mechanisms (Clarke and
Barres, 2013). The matricellular proteins, secreted protein acidic
and rich in cysteine (SPARC, also known as osteonectin) and
SPARC-like 1 (SPARCL1, also known as synaptic cleft 1 (SC1)
or Hevin), are produced by astrocytes and regulate excitatory
synaptogenesis in vitro and in the developing CNS in vivo
(Kucukdereli et al., 2011). While SPARCL1 directly promotes
excitatory synapse formation, SPARC specifically antagonizes
the synaptogenic activity of SPARCL1 (Kucukdereli et al.,
2011). Both proteins are normally expressed in the adult CNS
(Kucukdereli et al., 2011; Lloyd-Burton and Roskams, 2012),
and longitudinal changes in SPARCL1 expression have been
documented in the setting of CNS disease; tissue levels decline
following experimental seizures but rise after focal ischemia
(Lively and Brown, 2008; Lively et al., 2011). Correlation with
both the number and function of existing excitatory synapses in
these disease settings has not been well reported.
We hypothesized that local tissue inflammation influences
synaptic plasticity in ventral gray matter of the lumbar
spinal cords of mice with EAE by dynamically regulating
astrocyte production of SPARCL1 and SPARC. Changes to the
synapses in direct contact with lumbar ventral motor neurons
could contribute to the expected hind limb paralysis that is
characteristic of this disease. We also speculated that similar
immunoregulatory effects could be reproduced in vitro using
primary astrocyte cultures. Data reported here shed further
light on the cellular and molecular underpinnings of reversible
neurologic deficits in CNS autoimmune demyelinating diseases.
Materials and Methods
Animals
Female C57BL/6 and SJL mice (8–10 weeks old) were obtained
from Harlan Laboratories (Indianapolis, IN) or the National
Cancer Institute (Frederick, MD). Animals were maintained
under specific pathogen-free conditions in accordance with
guidelines set by the National Institutes of Health (NIH). The
University of Michigan Committee on the Use and Care of
Animals approved all of our experimental procedures. Mice
were housed on a 10 h light/14 h dark cycle in ventilated cages
containing up to five animals each. Food and water were available
ad libitum.
Animal Manipulations
Active EAE was induced in SJL mice by subcutaneous (s.c.)
immunization with 100µg PLP139−155 peptide (Biosynthesis,
Lewisville, TX) emulsified in complete Freund’s adjuvant
(CFA, Difco, Detroit, MI) containing an additional 4mg/ml
heat killed Mycobacterium tuberculosis, H37Ra (Difco). Active
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EAE was induced in C57BL/6 mice by s.c. immunization
with 100µg myelin oligodendrocyte glycoprotein (MOG)35−55
peptide (Biosynthesis) emulsified in CFA supplemented with
4mg/ml heat killed Mycobacterium tuberculosis, H37Ra. Each
C57BL/6 mouse also received 300 ng of pertussis toxin (List
Biological Laboratories, Campbell, CA) via intraperitoneal (i.p.)
injection on the day of immunization and again 48 h later.
Following immunization, animals were observed daily for clinical
signs of EAE and were scored by blinded examiners using the
following scale: 0 = no signs of disease; 1 = flaccid tail or hind
limb weakness; 2 = flaccid tail, hind limb weakness and loss of
righting reflex; 3= partial hind limb paralysis; 4= complete hind
limb paralysis; 5=moribund or dead.
At predetermined disease stages, some mice were euthanized
via extensive transcardiac perfusion with phosphate-buffered
saline (PBS) under anesthesia. For Western blots, PCR
quantification of RNA transcripts, and ELISA and Luminex
assays done on tissue extracts, spinal cords were quickly
dissected for further processing. For immunohistochemical and
immunofluorescence studies, animals were perfused a second
time with chilled PBS containing 4% paraformaldehyde (PFA)
before dissection. For electron microscopy (EM) preparations,
animals were perfused with 0.1M Sorenson’s buffer, followed by
2.5% glutaraldehyde in Sorenson’s buffer before dissection.
Western Blot Analyses
Spinal cords were mechanically homogenized in a tissue lysis
buffer (10mM Tris, 1% sodium dodecyl sulfate (SDS), 1mM
sodium orthovandate, pH 7.6) supplemented with a commercial
protease inhibitor cocktail (Roche Life Science, Indianapolis,
IN). Tissue lysates were centrifuged to remove undigested
tissue debris and the total protein concentration of each
supernatant determined using the Pierce Coomassie Protein
Assay Reagent (Thermo Fisher Scientific, Rockford, IL). Samples
were boiled in 4x protein sample buffer and 20µg/well run on
SDS-polyacrylamide gels. Proteins were transferred to PVDF
membranes and blocked overnight at 4◦C in a 5% non-fat
skim milk solution in Tris-buffered saline (TBS) containing
0.5% Tween 20. Membranes were then incubated with a
primary antibody (anti-glial fibrillary acidic protein (GFAP),
clone GA5 (1:1000, EMD Millipore, Temecula, CA); anti-
synaptophysin, clone SP15 (1:500, EMD Millipore); or anti-
microtubule associated protein 2 (MAP2), clone AP20 (1:2000,
EMD Millipore)) for 1 h at room temperature. Following
five sequential washes, membranes were then incubated with
a species-specific horseradish peroxidase (HRP)-conjugated
secondary antibody (1:10,000, EMD Millipore) for 1 h at
room temperature. Membranes were washed again, and the
HRP signal detected using ECL Western blotting detection
reagent (GE Healthcare Bio-Sciences, Pittsburg, PA). After the
chemiluminescent signal of each blot was collected on x-ray film,
membranes were stripped using Western blot stripping buffer
(Thermo Fisher Scientific) and relabeled with β-actin loading
control antibody (1:5000, Thermo Fisher Scientific) using the
same steps described above. Once all the β-actin signals were
obtained, all band densities were quantified using the ImageJ
software package (NIH, Bethesda, MD). The band density for
each protein was first normalized to the β-actin signal detected
in the same lane, and naïve samples were then set to an arbitrary
expression level of 1.0. Relative protein expression across the full
course of EAE was determined compared to naïve controls, and
expression in 5 samples at each disease stage was analyzed for
statistical significance.
Tissue Processing, Staining and Imaging
Spinal cords were post-fixed for 6 h in 4% PFA in PBS,
cryopreserved overnight in 30% sucrose in PBS, and snap
frozen in Tissue-Tek CRYO-OCT Compound (Thermo Fisher
Scientific). Eight micron frozen sections were cut, collected on
SuperFrost Plus slides (Thermo Fisher Scientific) and stored
at −20◦C until staining. At that time, sections were brought
to room temperature, washed in PBS and boiled for 20min in
0.01M citric acid in PBS (pH 6.0) to unmask tissue antigens.
Tissue sections were then permeabilized for 5min in 0.1% Triton
X-100 in PBS and blocked for 30min in 5% normal rabbit serum
(NRS).
For immunofluorescence, sections were incubated for 1 h
at room temperature with goat anti-mouse SPARCL1 antibody
(1:250; R&D Systems, Minneapolis, MN). Sections were washed
3 times in PBS and incubated with rhodamine-conjugated
rabbit anti-goat secondary antibody (1:200, eBioscience, San
Diego, CA) for 1 h at room temperature. Sections were washed
again, blocked in 5% normal goat serum (NGS) in PBS, and
incubated for 1 h with anti-GFAP monoclonal antibody (1:250,
EMD Millipore). After washing 3 times in PBS, slides were
incubated with FITC-conjugated goat anti-mouse secondary
antibody (1:200, eBioscience). The sections were then washed,
nuclei counterstained with DAPI (0.5µg/ml), coverslipped and
imaged using a Nikon Ti-U inverted microscope equipped with a
CoolSNAP EZ CCD digital camera (Photometrics, Tucson, AZ)
supported by the NIS-Elements Basic Research acquisition and
analysis software package (Nikon Instruments, Melville, NY).
For immunoperoxidase staining, permeabilized sections were
first treated with 1% hydrogen peroxide in methanol to block
endogenous tissue peroxidase, and then blocked in 2% NGS.
Slides were washed, incubated with anti-GFAP (1:250), anti-
synaptophysin (1:150) or anti-MAP2 (1:100) for 1 h at room
temperature, washed again, and then treated with biotin-labeled
goat anti-mouse IgG (Vector Laboratories, Burlingame, CA)
at a 1:200 dilution for another hour at room temperature.
These steps were followed by sequential incubations with
avidin-DH-biotin complex (Vector Laboratories) and then
0.5mg/ml 3,3′-diaminobenzidine (Sigma-Aldrich, St. Louis,MO)
in PBS containing 0.01% hydrogen peroxide. All slides were
counterstained with hematoxylin and mounted with coverslips
for light microscopy. Selected slides were imaged using a Nikon
Ti-U inverted microscope equipped with a Nikon DS-Fi-1 digital
camera and supported by the NIS-Elements Basic Research
acquisition and analysis software package (Nikon Instruments
Inc., Melville, NY).
Spinal cord samples for EM were post-fixed overnight in
2.5% glutaraldehyde in 0.1M Sorenson′s buffer, pH 7.4, at 4◦C,
and then incubated in 1% osmium tetroxide. After numerous
washes in double distilled water, samples were stained with 3%
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uranyl acetate for 1 h, dehydrated in increasing concentrations
of ethanol, rinsed twice in propylene oxide, and embedded in
epoxy resin for sectioning. Seventy nanometer sections were
stained with uranyl acetate and lead citrate and examined
with a Philips CM100 transmission electron microscope at 60
kV. Images were recorded using an ORCA-HR digital camera
(Hamamatsu Photonics, Bridgewater, NJ) operated using AMT
software (Advanced Microscopy Techniques Corp., Danvers,
MA). Motor neurons were identified in lumbar ventral gray
matter based on their characteristicmorphology, and cell outlines
measured by quantitative morphometry. Synaptic density per
100µm of motor neuron cell contour was counted in 10 cells per
animal and 3 animals per experimental group. Each axosomatic
synapse was defined as having both a post-synaptic density and
multiple presynaptic vesicles. Synapses that had retracted from
an adjacent cell body were identified based on the presence of
synaptic vesicles only.
RNA Isolation and Quantitative Real-time PCR
RNA was extracted from the spinal cords of 5 naïve mice and 5
animals at each stage of EAE using TRIzol reagent (Invitrogen,
Carlsbad, CA) and precipitated with isopropyl alcohol. After
washing with 75% ethanol, RNA was suspended in RNase-free
water and a cDNA template was synthesized from 2µg of each
sample using the SuperScript III First-Strand Synthesis System
for RT-PCR (Invitrogen). Quantitative real-time PCR was then
performed from each cDNA (20µl reaction/well) using Taqman
master mix and a Bio-Rad iQ5 cycler (Hercules, CA). Real-
time PCR probes and primer sequences were designed to avoid
amplification of any contaminating genomic DNA and were
obtained from Integrated DNA Technologies (Coralville, IA)
with the following sequences:
sparcl1 probe:5′-AGGCTGAAAAACCTTCAGCA-3′,
sparcl1 sense: 5′-CTGACCACTCCAACCCAACT-3′,
sparcl1 antisense: 5′-TCCTCATCCTTCAGGTCCAC-3′
sparc probe: 5′-AAACATGGCAAGGTGTGTGA-3′
sparc sense: 5′-AATTTGAGGACGGTGCAGAG-3′
sparc antisense: 5′-AAGTGGCAGGAAGAGTCGAA-3′
β-actin probe: 5′-CCAGCCAGGTCCAGACGCAG-3′
β-actin sense: 5′-TGTGCTGTCCCTGTATGC-3′
β-actin antisense: 5′-ATGAGGTAGTCTGTCAGGTC-3′
All probes contained 5′ 6-FAM and 3′ Black Hole Quencher
modifications. Levels of sparcl1 and sparc transcripts were
calculated relative to β-actin using the following formula: 2ˆ[Ct
(β-actin)–Ct (Target gene)] × 1000, where Ct is the threshold
cycle at which the fluorescent signal became significantly higher
than background. Results presented reflect either relative tissue
sparcl1 or sparcmRNA expression or the sparcl1/sparc transcript
expression ratio in a minimum of 4 samples per group.
Primary Astrocyte Cultures
Primary astrocytes were cultured from the cortices of 2–6
days old C57BL/6 mice as previously described (Rainey-Barger
et al., 2011). Briefly, cortices were minced and trypsinized
into a single cell suspension and cells were plated into T-150
tissue culture flasks in DMEM supplemented with 10% fetal
bovine serum (FBS), 2mM L-glutamine, OPI media supplement
[1mM oxaloacetate, 0.45mM pyruvate, 0.2U/ml insulin (Sigma-
Aldrich)] and antibiotics. After reaching∼70% confluency, flasks
were shaken overnight at 200 RPM at 37◦C to remove microglia
from themore firmly adherent astrocytes. The attached cells were
then trypsinized and cultured in medium supplemented with
0.1mM L-leucine methyl ester (L-LME) to eliminate remaining
microglia. After 3 passages, cells were harvested, counted and
cultured overnight in 24-well plates (3 × 105 cells/well). The
next day, medium was changed and cells were mock treated or
stimulated with recombinant murine cytokines (R&D Systems)
at varying concentrations. Culture supernatants were collected at
defined intervals and stored at−80◦C until further use.
Measurement of SPARC and SPARCL1
Concentrations in Tissue Lysates and Astrocyte
Culture Supernatants
Spinal cord homogenates were prepared as described for
Western blots and used for ELISA assays. Astrocyte culture
supernatants were also analyzed directly by ELISA. Tissue-
derived or astrocyte-secreted SPARCL1 or SPARC levels
were quantified using commercial ELISA kits (Antibodies-
Online, Inc., Atlanta, GA) according to the manufacturer’s
instructions. The lower limit of detection for these assays was
78 pg/ml or pg/mg tissue protein. All tissue results reflect
SPARCL1:SPARC concentration ratios in a minimum of 4
samples per group. Results in culture supernatants reflect either
absolute SPARCL1 or SPARC concentrations, fold concentration
changes in cytokine-treated cells compared to untreated cells, or
SPARCL1:SPARC concentration ratios. All culture supernatant
data shown represent a single experiment with a minimum of 4
experimental replicates per condition performed a minimum of
2 times.
Measurement of Tissue Cytokine and Chemokine
Concentrations by Luminex Assays
Spinal cord homogenates were prepared as described forWestern
blots and ELISA assays, and used for subsequent Luminex
analysis. The Milliplex mouse 32-plex cytokine detection system
(EMD Millipore, Billerica, Massachusetts, USA) was used
according to the manufacturer’s instructions to quantify cytokine
and chemokine levels directly in spinal tissue extracts. Plates
were read on a Luminex 200 instrument (EMD Millipore), and
cytokine and chemokine concentrations (pg/ml) calculated by
the BioPlex manager software (BioRad) using standard curves.
Results presented reflect the mean ± SEM of cytokine or
chemokine quantities per milligram of total protein extracted
from spinal cord tissue from 3 animals at each time point. The
lower limit of detection for these assays was 4.5 pg/ml.
Statistical Analyses
The Prism 5.0 software package (GraphPad Software, La Jolla,
CA) was used for all statistical analyses. Results are expressed as
mean ± SEM. A one-way analysis of variance (ANOVA) with a
post-hoc Bonferroni’s multiple comparison test was used to assess
for differences over time. A Two-way ANOVA was used to assess
for differences between groups over time. In all cases, differences
at a p < 0.05 level were considered significant.
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Results
Mice with Relapsing EAE Exhibit Dynamic
Astrocytic and Synaptic Changes in Lumbar
Spinal Gray Matter
Immunization of female SJL mice with the myelin peptide,
PLP139−151, produced a relapsing form of EAE where the initial
hind limb paralysis remitted from peak disease severity over just
a few days (Figure 1A). In this disease setting, we found that
astrocyte activation in the lumbar spinal cord, as assessed by
Western blot expression of the intermediate filament protein,
GFAP, preceded the onset of symptoms, reached a peak as hind
limb paralysis emerged, and declined with clinical remission
(Figure 1B). While inflammatory cell infiltration predominated
in the surrounding white matter tracts of mice with relapsing
EAE (data not shown), GFAP expression changes were identified
by immunohistochemistry in both gray and white matter regions
of the lumbar spinal cord at peak disease (Figure 1D) compared
to naïve controls (Figure 1C). These dynamic astroglial responses
in spinal gray matter raised the possibility that interactions with
adjacent neurons might also change over the course of relapse
and remission.
To survey the general integrity of synapses in the lumbar
spinal cords of mice with relapsing EAE, tissue expression
of the pre-synaptic neuronal protein, synaptophysin, and the
post-synaptic neuronal protein, MAP2, were assessed. By
immunohistochemistry both proteins localized exclusively to
spinal gray matter (Figure 2A), and by Western blot both
FIGURE 1 | Astrocytes are activated in both gray and white matter of
the lumbar ventral spinal cord during relapsing EAE. (A) The clinical
course of relapsing EAE induced by active PLP peptide immunization of SJL
mice shows near complete resolution of paralysis over only a few days
(n = 20). (B) Normalized spinal cord GFAP levels at defined stages of relapsing
EAE shows evidence of astrocyte activation at disease onset (n = 5 samples
per disease stage). (C) Representative immunohistochemical staining for
GFAP expression in naïve SJL spinal cord shows expression in
quiescent-appearing cells that predominate in white matter. Insert shows
modest signal in ventral gray matter. (D) Representative GFAP staining of SJL
spinal cord at peak EAE shows increased signal in both white and gray matter.
Insert shows numerous activated GFAP+ astrocytes in ventral gray matter.
*p < 0.05 compared to preclinical levels, Bar = 100µm.
proteins were dynamically regulated in directions opposite
to paralysis severity (i.e., levels declined as paralysis scores
increased, and vice versa) (Figure 2B). Focusing on the motor
pathway at an ultrastructural level, the actual number of synapses
found in direct contact with the perikarya of lumbar spinal motor
neurons were notably reduced at peak disease but recovered
as motor function returned back to normal (Figures 3A,B). At
peak disease, few of these axosomatic synapses showed evidence
that another cell had interposed a process between itself and
the neuronal cell body; most appeared to have simply retracted
from the cell perimeter (Figures 3C,D). Together, these data
suggest that physical changes to the synapses projecting directly
onto ventral motor neurons or their dendritic processes could
contribute to the fluctuating paralysis that typifies relapsing-
remitting EAE. They also show that dynamic modulation of
these synaptic connections occurs in both temporal and spatial
proximity to reactive astrocytes in surrounding gray matter.
Altered Expression of SPARCL1 and SPARC
mRNA and Protein Levels in the Lumbar Spinal
Cord Over the Course of EAE
The matricellular proteins, SPARC and SPARCL1, are produced
by astrocytes and regulate excitatory synaptogenesis in vitro
and in the developing CNS in vivo (Kucukdereli et al.,
2011). While SPARCL1 directly promotes excitatory synapse
formation, SPARC specifically antagonizes its synaptogenic
activity (Kucukdereli et al., 2011). Both proteins are expressed
in the adult CNS (Lloyd-Burton and Roskams, 2012), although
FIGURE 2 | Expression of synaptic proteins in lumbar spinal gray
matter is dynamically regulated during relapsing EAE. (A) Representative
immunohistochemical staining for the presynaptic protein, synaptophysin, and
the postsynaptic protein, MAP2, shows that both proteins localize to lumbar
spinal gray matter at varying stages of relapsing EAE in SJL mice. Inserts show
that synaptophysin labels gray matter neuropil while MAP2 labels neuronal cell
bodies and proximal dendrites. (B) Normalized expression of both proteins
shows reduced levels at peak disease, but notable recovery by the time of
disease remission only a few days later (n = 5 samples per disease stage). Bar
= 80µm, *p < 0.05 compared to preclinical levels.
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FIGURE 3 | The number of synapses in direct contact with the proximal
dendrites or cell bodies of lumbar ventral motor neurons changes over
the course of relapsing EAE. (A) A representative electron micrographic
image showing the proximal dendrite of a ventral motor neuron (green) with
multiple postsynaptic densities (arrows) indicative of individual synapses (red),
Bar = 500 nm. (B) Quantification of these synaptic contacts at different stages
of relapsing EAE shows evidence of synaptic retraction from the perikarya of
motor neurons (MN) at peak disease with full reestablishment of these
structures around MN several days later in the setting of disease remission
(n = 10 MN from each of 3 mice at each disease stage), *p < 0.05 naïve
versus peak and peak versus remission. (C) A representative electron
micrograph at peak disease shows many synapses (red, with arrows)
displaced from a motor neuron cell body (green), Bar = 2µm. (D) Another
representative electron micrograph at higher magnification shows the physical
separation of an axosomatic synapse (red) from the cell body of a ventral
motor neuron (green), without any other cellular process interposed between
the two structures, Bar = 500 nm.
their direct effects over existing excitatory synapses has not
been reported. Given dynamic changes to both astrocytes and
synapses in the lumbar gray matter of mice with relapsing EAE
(Figures 1–3), we investigated whether local tissue expression
of either SPARCL1 or SPARC changed over the course of this
disease. Real-time PCR analysis showed that sparcl1 transcript
levels declined in lumbar spinal cord with the onset of CNS
inflammation, were further suppressed at peak disease, but then
increased during remission in SJL mice with EAE (Figure 4A).
Transcript levels of its known inhibitor, sparc, also declined
during the preclinical stage of disease but increased thereafter
(Figure 4B).When sparcl1:sparc transcript ratios were calculated,
a dramatic, but transient, shift favoring synapse inhibition was
seen at peak disease (Figure 4C). A similar pattern in the
SPARCL1:SPARC protein expression ratios was observed in
spinal cord tissues over the course of disease when each protein
was measured by ELISA (Figure 4D).
When non-relapsing EAE was induced in C57BL/6 mice
following immunization with the MOG35−55 peptide, SPARCL1
co-localized with GFAP expression in both gray and white matter
(Figures 5A,B), and sparcl1 transcripts also declined in the
lumbar spinal cord as mice transitioned from preclinical to peak
disease (Figure 5C). In this setting, sparc levels did not change
over time (Figure 5D), but the sparcl1:sparc transcript ratio
FIGURE 4 | Expression of both sparcl1 and sparc transcripts and
SPARCL1 and SPARC proteins changes in lumbar spinal cord tissue
over the course of relapsing EAE in SJL mice. (A) Relative sparcl1 mRNA
expression fluxes over the course of relapsing EAE (n = 5 mice per disease
stage). (B) Relative sparc mRNA expression also changes over the course of
relapsing EAE (n = 5 mice per disease stage). (C) The calculated sparcl1 to
sparc mRNA expression ratio shifts in favor of synapse inhibition at peak
disease. (D) The same change in the SPARCL1 to SPARC protein
concentration ratios is seen over the course of relapsing EAE (n = 5 mice per
disease stage). *p < 0.05 compared to levels found in naïve spinal cord.
and the SPARCL1:SPARC protein ratio also declined as disease
symptoms became severe (Figures 5E,F). Together, these data
show that factors present in the spinal cord suppress astrocyte
production of synaptogenic proteins during peak EAE even as
these cells assume an activated phenotype.
Pro- and Anti-inflammatory Cytokines and
Chemokines Get Induced in the Spinal Cord
During EAE, and T Cell-derived Factors Regulate
Astrocyte Production of SPARCL1 and SPARC In
vitro
Hind limb paralysis in mice with EAE is driven by local CNS
inflammation initiated by myelin-specific CD4+ T cells. In this
setting, a wide range of cytokines and chemokines get induced
in the spinal cord at peak disease (Table 1). We used primary
glial cell cultures to investigate whether some of these mediators
directly altered astrocyte production of SPARCL1 or SPARC,
focusing on those factors made directly by encephalitogenic
CD4+ T cells. Primary astrocytes released substantial amounts
of SPARCL1 into culture supernatants without any direct
provocation (Figure 6A). When cells were treated with varying
concentrations of T cell-derived cytokines, a wide range of effects
on SPARCL1 production was observed. IFN-γ, the prototype
Th1 pro-inflammatory cytokine, modestly increased SPARCL1
levels in astrocyte culture supernatant (Figure 6B), while the
canonical Th17 cytokine, IL-17, had no effects on SPARCL1
release (Figure 6C). The anti-inflammatory cytokine, IL-10,
potently increased astrocyte SPARCL1 production (Figure 6D).
Granulocyte-macrophage colony stimulating factor (GM-CSF)
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FIGURE 5 | Expression of sparcl1 and sparc transcripts and SPARCL1
and SPARC proteins changes in lumbar spinal cord tissue over the
course of non-relapsing EAE in C57BL/6 mice. (A,B) Representative
immunofluorescence shows SPARCL1 expression co-localizes with GFAP
staining in both white and gray matter of the spinal cord, Bar = 40µm. (C)
Relative sparcl1 mRNA expression fluxes over the course of non-relapsing
EAE (n = 5 mice per disease stage). (D) Relative sparc mRNA expression does
not change over the course of non-relapsing EAE (n = 5 mice per disease
stage). (E) The calculated sparcl1 to sparc mRNA expression ratio shifts in
favor of synapse inhibition at peak disease. (F) A similar change in the
SPARCL1 to SPARC protein concentration ratios is seen over the course of
non-relapsing EAE (n = 5 mice per disease stage). *p < 0.05 compared to
levels found in naïve spinal cord.
also potently increased SPARCL1 levels (Figure 6E), even though
it also serves as an important effector in Th17-driven EAE
by mobilizing myeloid cells to the CNS (Kroenke et al., 2008;
Codarri et al., 2011). Finally, TNF-α suppressed SPARCL1
release (Figure 6F). We conclude that as a group, T cell-derived
cytokines exert complex effects on astrocyte SPARCL1 release.
Practical considerations prevented us from examining the extent
to which the many candidate non-T cell-derived cytokines
and chemokines influenced SPARCL1 production. Nonetheless,
astrocytes express a wide range of cytokine and chemokine
receptors meaning that other mediators could also contribute to
the effects observed in vivo (Farina et al., 2007).
Spontaneous astrocyte production of SPARC was also robust
(Figure 7A), although fewer of the cytokines tested modulated
its release. TNF-α modestly increased SPARC production by
these cells (Figure 7B), thereby shifting the SPARCL1:SPARC
TABLE 1 | Concentrations of various inflammatory mediators in the spinal
cords of mice at peak EAE (n = 3).
Mediator Concentration (pg/mg of total spinal cord tissue protein
(±SEM)
IFN-γ 36.39 ± 18.69
IL-1α 144.41 ± 80.26
IL-1β 6.20 ± 6.20
IL-2 77.41 ± 28.79
IL-6 5.47 ± 3.81
IL-7 6.80 ± 3.71
IL-9 2020.41 ± 938.06
IL-10 284.42 ± 262.74
IL-12p40 10.73 ± 6.25
IL-12p70 30.29 ± 16.92
IL-13 144.62 ± 94.11
IL-15 44.38 ± 22.21
IL-17 70.03 ± 50.18
CCL2 66.06 ± 28.42
CCL3 43.99 ± 27.44
CCL4 18.07 ± 9.61
CCL5 25.97 ± 12.92
CCL11 26.22 ± 13.32
CXCL1 101.45 ± 28.88
CXCL2 59.31 ± 38.81
CXCL5 25.01 ± 25.01
CXCL9 883.77 ± 529.62
CXCL10 260.23 ± 151.37
GM-CSF 43.91 ± 33.54
M-CSF 41.25 ± 25.74
TNF-α 94.31 ± 50.79
VEGF 8.36 ± 6.60
Below the stated assay limit of detection: G-CSF, IL-3, IL-4, IL-5, LIF.
concentration ratio more in favor of synapse inhibition
(Figure 7C). An opposite effect on this ratio was induced by
IL-10 (Figure 7D), a change largely driven by its induction
of SPARCL1 in astrocytes (Figure 6D). Both IFN-γ and IL-17
had no significant effect on SPARC release (data not shown).
Nonetheless, these data show that in vitro production of this anti-
synaptogenic molecule by astrocytes is also under some dynamic
control by T cell-derived inflammatory mediators.
Discussion
Gray matter pathology is increasingly recognized in MS
patients, even if its origins remain poorly understood. In some
circumstances, axonal damage in white matter lesions leads
to retrograde degeneration in the cerebral cortex, eventually
causing loss of cortical volume (Calabrese et al., 2015). In other
settings, gray matter damage occurs fully independent of white
matter injury causing what has been described as “outside-in”
brain pathology (Calabrese et al., 2015). Proposed mechanisms
for this latter form of damage include: (a) immune-mediated
events arising from perivascular infiltrates directly in gray matter
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FIGURE 6 | T cell-derived cytokines regulate astrocyte production of SPARCL1 in a complex manner in vitro. (A) Astrocytes spontaneously secrete
measurable amounts of SPARCL1 into culture supernatants (n = 4 experimental replicates per time point). (B) Interferon-gamma (IFN-γ) modestly increases astrocyte
SPARCL1 release (n = 3 experimental replicates per time point), p = 0.003 comparing changes over time. (C) Interleukin (IL)-17 has no significant effect on astrocyte
SPARCL1 production (n = 3 experimental replicates per time point). (D) IL-10 potently induces astrocyte SPARCL1 production (n = 3 experimental replicates per time
point), p = 0.0003 comparing changes over time, p = 0.002 comparing fold change differences. (E) Granulocyte macrophage colony stimulating factor (GM-CSF)
potently induces astrocyte SPARCL1 production (n = 3 experimental replicates per time point), p = 0.0024 comparing changes over time. (F) Tumor necrosis factor
(TNF)-α suppresses astrocyte SPARCL1 production (n = 3 experimental replicates per time point), p = 0.0384 comparing fold change differences.
parenchyma or in focal lymphoid-like structures found in the
overlying meninges (Serafini et al., 2004; Magliozzi et al., 2010;
Lucchinetti et al., 2011; Calabrese et al., 2015), (b) aberrant
activation of gray matter microglia (Peterson et al., 2001; Dutta
and Trapp, 2007), and/or (c) activation of non-inflammatory
degenerative pathways (some possibly related to mitochondrial
dysfunction) targeting neurons, oligodendrocytes or astrocytes
that only trigger inflammation as a secondary event (Barnett and
Prineas, 2004; Mahad et al., 2008; Henderson et al., 2009). In
all such scenarios, primary neuronal loss in cortical gray matter
would cause anterograde degeneration of axons in downstream
white matter pathways. Imaging data obtained in early RRMS
patients with comparable white matter lesion loads show that
clinical disability progresses faster in those individuals with more
widespread gray matter atrophy (Calabrese et al., 2015). These
and other findings argue that the mechanisms underlying gray
matter pathology must be understood and accounted for by new
therapies designed to slow or halt MS progression.
Synapses are the main interface whereby networks of neurons
interact with each other during normal nervous system function.
More and more studies find synaptic abnormalities and gray
matter lesions inMS patients (Vercellino, 2005; Stadelmann et al.,
2008; Michailidou et al., 2015). Dysfunction or loss of synapses
could allow for the emergence of neurological deficits without
corresponding white matter pathology, and dynamic changes to
synapses could easily produce deficits that fluctuate over time.
While direct imaging synaptic changes in living humans is not
yet feasible, two-photon intravital microscopy has been used to
visualize axonal boutons and dendritic spines in the cortices of
mice with EAE in real time. One such study showed notable
synaptic instability during disease, often starting well before
immune cell infiltration or the onset of overt symptoms (Yang
et al., 2013). TNF-α was implicated in these cortical synaptic
changes as the fluctuations were suppressed with a TNF inhibitor
(Yang et al., 2013). Even in the absence of a disease such as EAE,
TNF-α has been shown to regulate homeostatic synaptic scaling
in a way that optimizes the performance of neural networks
(Stellwagen and Malenka, 2006). Thus, at least one inflammatory
mediator is closely linked to the structure and function of
synapses during both health and disease.
A recent study by Chen et al. demonstrated that activated
microglia transiently displace synapses from the perikarya of
cortical neurons as a neuroprotective response (Chen et al.,
2014). In this setting, microglia closely oppose themselves
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FIGURE 7 | Some T cell-derived cytokines regulate astrocyte production of SPARC in vitro. (A) Astrocytes spontaneously secrete measurable amounts of
SPARC into culture supernatants (n = 4 experimental replicates per time point). (B) TNF-α modestly induces astrocyte SPARC production (n = 3 experimental
replicates per time point). (C) TNF-α suppresses the ratio of SPARCL1 to SPARC made by astrocytes over time, p < 0.0001 comparing ratio differences, p = 0.0002
comparing changes over time. (D) IL-10 augments the ratio of SPARCL1 to SPARC made by astrocytes over time, p < 0.0001 comparing ratio differences,
p < 0.0001 comparing changes over time.
to neuronal cell bodies and physically displace inhibitory
GABAergic synapses, thereby increasing the synchronized
firing of cortical neurons and augmenting their expression of
antiapoptotic and neurotrophic molecules (Chen et al., 2014).
This process differs from the pruning of synapses by microglia
during development in that it rapidly resolves itself and does not
require complement deposition (Chen et al., 2014). Although we
find activated microglia in lumbar gray matter during EAE (data
not shown), we do not find convincing ultrastructural evidence
that microglial cell processes interpose themselves between
motor neuron cell bodies and displaced presynaptic terminals
(Figures 3C,D). We believe our data are more compatible with
a transient disruption of a preexisting synaptic maintenance
system, rather than any active synaptic stripping by another
cell type.
Astrocytes are now recognized to support the formation,
maturation, activity, and elimination of neuronal synapses
(Clarke and Barres, 2013; Haydon andNedergaard, 2014; De Pittà
et al., 2015). While such cellular interactions are most apparent
during development (Allen and Barres, 2005; Christopherson
et al., 2005; Eroglu et al., 2009; Kucukdereli et al., 2011; Allen
et al., 2012; Clarke and Barres, 2013; Haydon and Nedergaard,
2014; De Pittà et al., 2015), there is growing evidence they
continue into adulthood. For example, astrocytes were recently
shown to continuously engulf synapses in the normal adult
brain (Chung et al., 2013). This active synaptic remodeling
implies that astrocytes could play an important role in basic
brain functions such as learning and memory. Furthermore,
astrocyte-driven synaptic plasticity appears important for the
recovery from acute CNS injury; one study showed that the
astrocyte proteins, thrombospondin (TSP)-1 and TSP-2, facilitate
the reestablishment of synapses and promote the functional
recovery of mice following experimental stroke (Liauw et al.,
2008). Our data show a dynamic regulation of astrocyte-derived
SPARCL1 and SPARC by local factors in the spinal cord,
implying that dysfunction of these cellular processes is intrinsic
to EAE itself. In other words, while astrocyte-driven synaptic
plasticity may be important for both normal development and
the host response to acute CNS injury, this adaptive process
can also be subverted as part of a disease process. An improved
understanding of when and how to shift astrocytes toward the
maintenance of synapses and away from synapse inhibition
could open up novel therapeutic strategies for disorders such
as RRMS.
Our study correlates in vitro and in vivo findings to draw links
between changing levels of astrocyte-derived proteins involved in
synaptic homeostasis, local tissue inflammation and EAE disease
severity. It does do not confirm any cause-and-effect link between
these events. Nonetheless, the data do support our hypothesis
that local tissue inflammation influences both synaptic plasticity
in lumbar ventral gray matter as well as clinical symptoms in
mice with EAE by dynamically regulating astrocyte production
of proteins such as SPARCL1 and SPARC. Our in vitro data
show that T cell-derived cytokines can directly control astrocyte
production of these matricellular proteins, and it seems likely
that tissue expression of these proteins over the course of EAE
is the result of local astrocytes integrating the effects of the
inflammatory milieu around them. Our ongoing studies aim to
show that inducible over-expression or direct replacement of
SPARCL1, or timed neutralization of SPARC, can ameliorate the
severity of EAE paralysis in order to more directly prove these
astrocytic changes contribute to disease. If confirmed, this would
represent the first therapeutic strategy that direct targets glial cells
in this disorder.
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